Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL

NCT06695013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

144

Enrollment

OTHER

Sponsor class

Conditions

B-NHL
CART Therapy

Interventions

DRUG: zanubrutinib
DRUG: CAR-T
RADIATION: Bridging radiotherapy
DRUG: Tislelizumab

Sponsor

Ruijin Hospital